Besides the cysteines, the only invariant residues are the arginines in B13, Bl7, the glycines in B12, B24, and the glycine in A14. The backbone is lightly shaded.
The receptor-binding site
On the basis of earlier studies, the two arginine residues in positions B13 and B17 were targeted for exchange with the isosteric, but uncharged, amino acid citrulline (Fig. 3) . The first three derivatives, namely, B13 Cit, Bl7 Cit, and Bl3, B17 bis-Cit, were inactive in the mouse symphysis pubis bioassay as well as in the mouse brain receptor-binding assay. Both arginines were absolutely essential for relaxin activity; the remaining arginines in relaxin appeared to be uninvolved (1, 2). The important arginines are located in an n, n + 4 position in the midsection of the B chain helix, their side chains pointing outward into the surrounding water (Fig. 4) The A chain loop is type-specific for relaxin and insulin, but alanine in position A14 (AlO respectively) is a compromise that allows both hormones to retain receptorbinding capacity.
In relaxin, the A chain loop points away from the receptor-binding site, yet the effect is dramatic and the X-ray crystallographic analysis of the native hormones clearly points to a different conformation of the two A chain loops (6) (Fig. 5) .
The possibility that it is not A14 (AlO) but rather the entire loop that needs to be changed in toto in order to provide the proper conformation for the recipient molecule has been eliminated by an experiment involving the synthesis of a human relaxin with a complete insulin loop substitution. The Thr-Ser-Ile (A12 to A14) relaxin was inactive as well. A mechanistic explanation is that the insulin loop needs to be restricted and that this restriction is achieved by the bulky side-chain residue on AlO (either Ile or Val), which is too large to fit the limited space between the loop and the core of the molecule and thus force the A chain loop in insulin into a more upright position.
In relaxin, the proton of glycine can easily be accommodated so that the relaxin loop can lie flat (Fig. 6 ). It appears that the relaxin loop has more degrees of freedom, and therefore extreme flexibility was built into the loop by substituting w-aminooctanoic acid (Aoc) for all loop residues.
In this derivative, the center of the A chain was essentially an aliphatic hydrocarbon. The Aoc relaxin still retained a measurable level of activity, but when in a different derivative the cysteines AlO and A15 were replaced by serines, thus eliminating the loop altogether, the activity disappeared.
It is still possible that it is the presence of serine rather than the absence of the loop that inactivates relaxin, but either way, this seemed to be an interesting and unexpected story of insulin and its structural homologue relaxin (Table 1) .
The invariant B chain glycines
The receptor-binding site-containing major helix of the B chain lies between cysteines Bli and B23, which form the interchain cross-links.
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The FASEB Journal SCHWABE AND BULLESBACH Table 1 suggest that relaxins would have performed just as well with alanine in position B12 and certainly would have retained functionality with alanine in B24, so the constancy of these glycine residues takes on a different meaning. The assumption that constantly appearing residues are also functionally important is not always correct.
The peculiar mouse relaxin
The If all of this is indeed an effect of relaxin, the mechanism of relaxin action in peripheral tissues is unknown. During a recent meeting of relaxin researchers in Adelaide, Australia, the possibility was raised that relaxin works in part through a nitric oxide mechanism.
In addition, relaxin receptors that once were thought to be unique for the reproductive tract have been found in many places in the body such as the brain (70) (71) (72) , heart atria (73), and even in fibroblasts (74, 75). The relaxin receptors in the atria have been associated with a strong ionotrophic and chronotrophic effect on the rat heart (20, 76, 77).
The prospect that relaxin could be an important pharmacological agent with regard to blood flow takes on a different dimension if one considers that in the United States alone 50,000 amputations are performed each year because of blood flow problems, and that the majority of these patients are diabetic.
In 
